MedTrace Logo

Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis

NCT02778919 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-06-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety, and dose-response relationship of KLH-2109 compared to placebo in Japanese patients with endometriosis.

Conditions

  • Endometriosis

Interventions

DRUG

KLH-2109

DRUG

Placebo

DRUG

Leuprorelin acetate

Sponsors & Collaborators

  • Kissei Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-09
Primary Completion
2018-03-23
Completion
2018-03-23

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02778919 on ClinicalTrials.gov